相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Specific delivering of RNAi using Spike's aptamer-functionalized lipid nanoparticles for targeting SARS-CoV-2: A strong anti-Covid drug in a clinical case study
Haidar Saify Nabiabad et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2022)
A siRNA targets and inhibits a broad range of SARS-CoV-2 infections including Delta variant
Yi-Chung Chang et al.
EMBO MOLECULAR MEDICINE (2022)
Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study
Paolo Ventura et al.
LIVER INTERNATIONAL (2022)
The UCSC Genome Browser database: 2022 update
Brian T. Lee et al.
NUCLEIC ACIDS RESEARCH (2022)
Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics
P. Vervaeke et al.
ADVANCED DRUG DELIVERY REVIEWS (2022)
Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation
Hartmut H. Schmidt et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2022)
Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria
Bernd Hoppe et al.
KIDNEY INTERNATIONAL (2022)
Identification of the toxic 6mer seed consensus for human cancer cells
Monal Patel et al.
SCIENTIFIC REPORTS (2022)
Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2
Maik Friedrich et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2022)
Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects
Bahru A. Habtemariam et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria
Prajakta Badri et al.
CLINICAL PHARMACOKINETICS (2021)
Database resources of the National Center for Biotechnology Information
Eric W. Sayers et al.
NUCLEIC ACIDS RESEARCH (2021)
Lumasiran: First Approval
Lesley J. Scott et al.
DRUGS (2021)
Gene regulation by long non-coding RNAs and its biological functions
Luisa Statello et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2021)
Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort
K. John Pasi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)
A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma
Priya Kumthekar et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation
Musa Khaitov et al.
ALLERGY (2021)
Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1 A Placebo-Controlled Randomized Clinical Trial
Yaacov Frishberg et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
Givosiran: A Review in Acute Hepatic Porphyria
Yahiya Y. Syed
DRUGS (2021)
A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19
Adi Idris et al.
MOLECULAR THERAPY (2021)
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Sander F. Garrelfs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Teprasiran, a Small Interfering RNA, for the Prevention of Acute Kidney Injury in High-Risk Patients Undergoing Cardiac Surgery A Randomized Clinical Study
Matthias Thielmann et al.
CIRCULATION (2021)
Ensembl 2021
Kevin L. Howe et al.
NUCLEIC ACIDS RESEARCH (2021)
Inclisiran-New hope in the management of lipid disorders?
Krzysztof Dyrbus et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2020)
Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin-Mediated Amyloidosis
Xiaoping Zhang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria
Sagar Agarwal et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Extracellular vesicle (ECV)-modified polyethylenimine (PEI) complexes for enhanced siRNA delivery in vitro and in vivo
Petro Zhupanyn et al.
JOURNAL OF CONTROLLED RELEASE (2020)
A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT).
Anna M. Varghese et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Imaging small molecule-induced endosomal escape of siRNA
Hampus Du Rietz et al.
NATURE COMMUNICATIONS (2020)
The Role of lncRNAs TAPIR-1 and-2 as Diagnostic Markers and Potential Therapeutic Targets in Prostate Cancer
Maik Friedrich et al.
CANCERS (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phosphorothioate modified oligonucleotide-protein interactions
Stanley T. Crooke et al.
NUCLEIC ACIDS RESEARCH (2020)
Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease
Christine I. Wooddell et al.
JCI INSIGHT (2020)
Therapeutic siRNA: state of the art
Bo Hu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
2019 FDA TIDES (Peptides and Oligonucleotides) Harvest
Danah Al Shaer et al.
PHARMACEUTICALS (2020)
RIG-I-like receptors: their regulation and roles in RNA sensing
Jan Rehwinkel et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Therapeutic Antisense Oligonucleotides Are Coming of Age
C. Frank Bennett
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference
Andrew A. Butler et al.
JOURNAL OF LIPID RESEARCH (2019)
The current state and future directions of RNAi-based therapeutics
Ryan L. Setten et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
Eliane Sardh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety evaluation of 2-deoxy-2-fluoro nucleotides in GalNAc-siRNA conjugates
Maja M. Janas et al.
NUCLEIC ACIDS RESEARCH (2019)
Strategies, design, and chemistry in siRNA delivery systems
Yizhou Dong et al.
ADVANCED DRUG DELIVERY REVIEWS (2019)
Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index
Wen Shen et al.
NATURE BIOTECHNOLOGY (2019)
Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins
Michael T. Migawa et al.
NUCLEIC ACIDS RESEARCH (2019)
Regulating intracellular fate of siRNA by endoplasmic reticulum membrane-decorated hybrid nanoplexes
Chong Qiu et al.
NATURE COMMUNICATIONS (2019)
Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery
Byungji Kim et al.
ADVANCED MATERIALS (2019)
Perspectives, issues and solutions in RNAi therapy: the expected and the less expected
Achim Aigner
NANOMEDICINE (2019)
Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis: Analysis of the APOLLO Study
Scott D. Solomon et al.
CIRCULATION (2019)
PCSK9-gene-silencing, cholesterol-lowering drug impresses
Cormac Sheridan
NATURE BIOTECHNOLOGY (2019)
Acute Hepatic Porphyrias: Review and Recent Progress
Bruce Wang et al.
HEPATOLOGY COMMUNICATIONS (2019)
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Xiulong Shen et al.
NUCLEIC ACIDS RESEARCH (2018)
Tivanisiran, a novel siRNA for the treatment of dry eye disease
Javier Moreno-Montanes et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Noncoding RNAs in disease
Evangelia Lekka et al.
FEBS LETTERS (2018)
Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria
Chengjung Lai et al.
MOLECULAR THERAPY (2018)
Advanced siRNA Designs Further Improve In Vivo Performance of GaINAc-siRNA Conjugates
Donald J. Foster et al.
MOLECULAR THERAPY (2018)
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
D. Adams et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics
Aaron D. Springer et al.
NUCLEIC ACID THERAPEUTICS (2018)
Liver-Targeted Anti-HBV Single-Stranded Oligonucleotides with Locked Nucleic Acid Potently Reduce HBV Gene Expression In Vivo
Hassan Javanbakht et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Long noncoding RNAs: regulation, function and cancer
Aras Rafiee et al.
BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, VOL 34, ISSUE 2 (2018)
An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B
Nicoletta Machin et al.
JOURNAL OF BLOOD MEDICINE (2018)
siRNA carrying an (E)-vinylphosphonate moiety at the 5′ end of the guide strand augments gene silencing by enhanced binding to human Argonaute-2
Elad Elkayam et al.
NUCLEIC ACIDS RESEARCH (2017)
Synthesis of 5′-GalNAc-Conjugated Oligonucleotides: A Comparison of Solid and Solution-Phase Conjugation Strategies
Isaiah Cedillo et al.
MOLECULES (2017)
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Sushrut Kamerkar et al.
NATURE (2017)
The chemical evolution of oligonucleotide therapies of clinical utility
Anastasia Khvorova et al.
NATURE BIOTECHNOLOGY (2017)
Overcoming cellular barriers for RNA therapeutics
Steven F. Dowdy
NATURE BIOTECHNOLOGY (2017)
Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
K. J. Pasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
5′-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo
Reka A. Haraszti et al.
NUCLEIC ACIDS RESEARCH (2017)
Strategies for Improving siRNA-Induced Gene Silencing Efficiency
Fatemeh Safari et al.
ADVANCED PHARMACEUTICAL BULLETIN (2017)
Safety and Tolerability Study of an Intravenously Administered Small Interfering Ribonucleic Acid (siRNA) Post On-Pump Cardiothoracic Surgery in Patients at Risk of Acute Kidney Injury
Segav Demirjian et al.
KIDNEY INTERNATIONAL REPORTS (2017)
Precise and efficient siRNA design: a key point in competent gene silencing
E. Fakhr et al.
CANCER GENE THERAPY (2016)
9 5′-(E)-Vinylphosphonate: A Stable Phosphate Mimic Can Improve the RNAi Activity of siRNA-GalNAc Conjugates
Rubina Parmar et al.
CHEMBIOCHEM (2016)
Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1
Chaitali Dutta et al.
MOLECULAR THERAPY (2016)
From the RNA world to the clinic
Bruce A. Sullenger et al.
SCIENCE (2016)
Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients without Inhibitors
Margaret V. Ragni et al.
BLOOD (2016)
Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease
Jose Manuel Benitez-Del-Castillo et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2016)
Hepatocyte-Specific Delivery of siRNAs Conjugated to Novel Non-nucleosidic Trivalent N-Acetylgalactosamine Elicits Robust Gene Silencing in Vivo
Kallanthottathil G. Rajeev et al.
CHEMBIOCHEM (2015)
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Andreas Wicki et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown
Anders Wittrup et al.
NATURE BIOTECHNOLOGY (2015)
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
Alfica Sehgal et al.
NATURE MEDICINE (2015)
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients
Talia Golan et al.
ONCOTARGET (2015)
Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification
Amy Chan et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
siRNA Versus miRNA as Therapeutics for Gene Silencing
Jenny K. W. Lam et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
Base Modification Strategies to Modulate Immune Stimulation by an siRNA
Rachel Anne P. Valenzuela et al.
CHEMBIOCHEM (2015)
Click Modification of RNA at Adenosine: Structure and Reactivity of 7-Ethynyl- and 7-Triazolyl-8-aza-7-deazaadenosine in RNA
Kelly J. Phelps et al.
ACS CHEMICAL BIOLOGY (2014)
Toll-Like Receptors in Antiviral Innate Immunity
Sandra N. Lester et al.
JOURNAL OF MOLECULAR BIOLOGY (2014)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice
Makiko Yasuda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Toxicological and Pharmacokinetic Properties of QPI-1007, a Chemically Modified Synthetic siRNA Targeting Caspase 2 mRNA, Following Intravitreal Injection
Elisabeth C. R. Solano et al.
NUCLEIC ACID THERAPEUTICS (2014)
Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling
Gaurav Sahay et al.
NATURE BIOTECHNOLOGY (2013)
Delivery materials for siRNA therapeutics
Rosemary Kanasty et al.
NATURE MATERIALS (2013)
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Teresa Coelho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Development of modified siRNA molecules incorporating 5-fluoro-2'-deoxyuridine residues to enhance cytotoxicity
Shao-yu Wu et al.
NUCLEIC ACIDS RESEARCH (2013)
Overview of Complement Activation and Regulation
Marina Noris et al.
SEMINARS IN NEPHROLOGY (2013)
Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles
Barbara L. Mui et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2013)
In Vitro-In Vivo Translation of Lipid Nanoparticles for Hepatocellular siRNA Delivery
Kathryn A. Whitehead et al.
ACS NANO (2012)
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo
Muthusamy Jayaraman et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo
Yusuke Sato et al.
JOURNAL OF CONTROLLED RELEASE (2012)
siRNA-optimized Modifications for Enhanced In Vivo Activity
Denise M. Kenski et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2012)
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
Jun Fang et al.
ADVANCED DRUG DELIVERY REVIEWS (2011)
Inhibiting the C5-C5a receptor axis
Trent M. Woodruff et al.
MOLECULAR IMMUNOLOGY (2011)
Elimination Pathways of Systemically Delivered siRNA
Yuanyu Huang et al.
MOLECULAR THERAPY (2011)
Rational design of cationic lipids for siRNA delivery
Sean C. Semple et al.
NATURE BIOTECHNOLOGY (2010)
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus
John DeVincenzo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Identifying druggable disease-modifying gene products
Scott J. Dixon et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
The Effect of Chemical Modification and Nanoparticle Formulation on Stability and Biodistribution of siRNA in Mice
Shan Gao et al.
MOLECULAR THERAPY (2009)
Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth
Won Gil Cho et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
COMBINATION THERAPY USING THE SMALL INTERFERING RNA BEVASIRANIB
Lawrence Singerman
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2009)
Problems associated with reporter assays in RNAi studies
Guihua Sun et al.
RNA BIOLOGY (2009)
Trivalent, Gal/GalNAc-containing ligands designed for the asialoglycoprotein receptor
Oleg Khorev et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
Chemically modified siRNA: tools and applications
Jonathan K. Watts et al.
DRUG DISCOVERY TODAY (2008)
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3
Mark E. Kleinman et al.
NATURE (2008)
The impact of target site accessibility on the design of effective siRNAs
Hakim Tafer et al.
NATURE BIOTECHNOLOGY (2008)
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akin Akinc et al.
NATURE BIOTECHNOLOGY (2008)
OligoWalk: an online siRNA design tool utilizing hybridization thermodynamics
Zhi John Lu et al.
NUCLEIC ACIDS RESEARCH (2008)
Thermodynamic stability and Watson-Crick base pairing in the seed duplex are major determinants of the efficiency of the siRNA-based off-target effect
Kumiko Ui-Tei et al.
NUCLEIC ACIDS RESEARCH (2008)
Efficient siRNA selection using hybridization thermodynamics
Zhi John Lu et al.
NUCLEIC ACIDS RESEARCH (2008)
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
Russell P. Rother et al.
NATURE BIOTECHNOLOGY (2007)
Effect of target secondary structure on RNAi efficiency
Yu Shao et al.
RNA (2007)
A protocol for designing siRNAs with high functionality and specificity
Amanda Birmingham et al.
NATURE PROTOCOLS (2007)
Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification
Sujiet Puthenveetil et al.
NUCLEIC ACIDS RESEARCH (2006)
Off-target effects by siRNA can induce toxic phenotype
Yuriy Fedorov et al.
RNA (2006)
Improvements in siRNA properties mediated by 2 '-deoxy-2 '-fluoro-beta-D-arabinonucleic acid (FANA)
T Dowler et al.
NUCLEIC ACIDS RESEARCH (2006)
Activation of the mammalian immune system by siRNAs
JT Marques et al.
NATURE BIOTECHNOLOGY (2005)
Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque
BJ Li et al.
NATURE MEDICINE (2005)
Sequence characteristics of functional siRNAs
B Jagla et al.
RNA (2005)
Purified Argonaute2 and an siRNA form recombinant human RISC
FV Rivas et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2005)
Algorithm for selection of functional siRNA sequences
M Amarzguioui et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Rational siRNA design for RNA interference
A Reynolds et al.
NATURE BIOTECHNOLOGY (2004)
Sfold web server for statistical folding and rational design of nucleic acids
Y Ding et al.
NUCLEIC ACIDS RESEARCH (2004)
Protection against lethal influenza virus challenge by RNA interference in vivo
SM Tompkins et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Functional siRNAs and rniRNAs exhibit strand bias
A Khvorova et al.
CELL (2003)
Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells
NS Lee et al.
NATURE BIOTECHNOLOGY (2002)
RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells
JY Yu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate
SM Elbashir et al.
EMBO JOURNAL (2001)
Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C-elegans
RF Ketting et al.
GENES & DEVELOPMENT (2001)
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
SM Elbashir et al.
NATURE (2001)
Initial sequencing and analysis of the human genome
ES Lander et al.
NATURE (2001)
RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals
PD Zamore et al.
CELL (2000)
分享论文
